

Summary of risk management plan for Fentanilo Isab 0.05 mg/ml solução injetável (Fentanyl Citrate)

This is a summary of the risk management plan (RMP) **Fentanilo Isab 0.05 mg/ml solução injetável**. The RMP details important risks **Fentanilo Isab 0.05 mg/ml solução injetável**, how these risks can be minimised, and how more information will be obtained about **Fentanilo Isab 0.05 mg/ml solução injetável** risks and uncertainties (missing information).

Fentanilo Isab 0.05 mg/ml solução injetável 's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how **Fentanilo Isab 0.05 mg/ml solução injetável** should be used.

Important new concerns or changes to the current ones will be included in updates of **Fentanilo Isab 0.05 mg/ml solução injetável** 's RMP.

I. The medicine and what it is used for

Fentanilo Isab 0.05 mg/ml solução injetável is authorised as a narcotic analgesic supplement in general or regional anaesthesia, in combination with a neuroleptic (e.g. droperidol) in the technique of neuroleptanalgesia, for the induction of anaesthesia, and as an adjuvant in the maintenance of general and regional anaesthesia and as an anaesthetic agent with oxygen in high-risk patients undergoing surgery. (see SmPC for the full indication). It contains fentanyl citrate as the active substance and it is given by intravenous route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of **Fentanilo Isab 0.05 mg/ml solução injetável**, together with measures to minimise such risks and the proposed studies for learning more about **Fentanilo Isab 0.05 mg/ml solução injetável**'s risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

II.A List of important risks and missing information

Important risks of **Fentanilo Isab 0.05 mg/ml solução injetável** are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of **Fentanilo Isab 0.05 mg/ml solução injetável**. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	None.
Important potential risks	None.
Missing information	- Use in pregnant women.

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of **Fentanilo Isab 0.05 mg/ml solução injetável**.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for **Fentanilo Isab 0.05 mg/ml solução injetável**.